Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 5/20 | 0.56 |
| ▸ | KDR | P35968 | 3/20 | 0.55 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 3/20 | 0.48 |
| ▸ | MMP9 | P14780 | 3/20 | 0.48 |
| ▸ | MMP8 | P22894 | 3/20 | 0.48 |
| ▸ | MMP13 | P45452 | 3/20 | 0.48 |
| ▸ | METAP2 | P50579 | 5/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4370849 | 0.85 | MEN1 (0.53) | METAP1KDRMETAP2SMN1; SMN2POLB | |
| SCHEMBL4371286 | 0.85 | MMP2 (0.62) | METAP1MMP2MMP9MMP8MMP13 | |
| SCHEMBL4375655 | 0.83 | MMP2 (0.64) | METAP1MMP2MMP9MMP8MMP13 | |
| SCHEMBL4371250 | 0.83 | METAP1 (0.58) | METAP1MMP2MMP9MMP8MMP13 | |
| SCHEMBL4371759 | 0.83 | MAPT (0.59) | METAP1METAP2RAB9AKDM4ENPC1 | |
| SCHEMBL13624132 | 0.82 | METAP1 (0.64) | METAP1KDRMETAP2RAB9AKDM4E | |
| SCHEMBL11208586 | 0.81 | METAP1 (0.63) | METAP1METAP2RAB9AKDM4ENPC1 | |
| SCHEMBL4363660 | 0.81 | METAP1 (0.56) | METAP1MMP2MMP9MMP8MMP13 | |
| SCHEMBL4371202 | 0.81 | KDR (0.55) | METAP1KDRMETAP2RAB9AKDM4E | |
| SCHEMBL4363482 | 0.81 | METAP1 (0.52) | METAP1KDRMETAP2RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1581217-A4 | CARBONYLAMINO-BENZIMIDAZOLE DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2007-07-11 | — | — | EP | claimed |
| US-20060036098-A1 | Carbonylamino-benzimidazole derivatives as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2006-02-16 | — | — | US | claimed |
| EP-1581217-A1 | CARBONYLAMINO-BENZIMIDAZOLE DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2005-10-05 | — | — | EP | claimed |
| WO-2004041277-A1 | CARBONYLAMINO-BENZIMIDAZOLE DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2004-05-21 | — | — | WO | claimed |
| US-7622592-B2 | Carbonylamino-benzimidazole derivatives as androgen receptor modulators | MERCK & CO., INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622592-B2 | Carbonylamino-benzimidazole derivatives as androgen receptor modulators | MERCK & CO., INC. (US) | 2009-11-24 | — | — | US | disclosed |
| EP-1581217-A4 | CARBONYLAMINO-BENZIMIDAZOLE DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2007-07-11 | — | — | EP | disclosed |
| US-20060036098-A1 | Carbonylamino-benzimidazole derivatives as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2006-02-16 | — | — | US | disclosed |
| EP-1581217-A1 | CARBONYLAMINO-BENZIMIDAZOLE DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004041277-A1 | CARBONYLAMINO-BENZIMIDAZOLE DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060036098-A1 | Carbonylamino-benzimidazole derivatives as androgen receptor modulators | AR, SHBG, BRCA1 | METAP1 3988/4885KDR 2254/4885NAMPT 3989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.